| 2026-08-06 | Press release | Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates |
| 2026-08-06 | Deck | Earnings presentation · Q2 2026 · Aug 2026 |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-06 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-30 | Press release | Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 |
| 2026-07-27 | Press release | Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obs |
| 2026-06-03 | Press release | Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions |
| 2026-05-28 | Press release | Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference |
| 2026-05-19 | Deck | First Quarter 2026 Earnings |
| 2026-05-07 | Press release | Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-06 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-04 | Press release | Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital |
| 2026-04-30 | Press release | Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-30 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-17 | Press release | Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting |
| 2026-03-24 | Press release | PDF Version |
| 2026-03-24 | Press release | Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo |
| 2026-03-23 | Press release | PDF Version |
| 2026-03-23 | Press release | Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 |
| 2026-03-16 | Annual report | Annual report · FY 2025 · Mar 2026 |
| 2026-03-16 | Proxy | Definitive proxy statement |
| 2026-03-11 | Press release | PDF Version |
| 2026-03-11 | Press release | Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients w |
| 2026-03-05 | Deck | 4th Quarter and Full Year Results 2025 Conference Presentation |
| 2026-03-05 | Press release | Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates |
| 2026-03-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-05 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-03 | Press release | PDF Version |
| 2026-03-03 | Press release | Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences |
| 2026-02-26 | Press release | Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 |
| 2026-02-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-01-29 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-21 | Press release | PDF Version |
| 2026-01-21 | Press release | Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabeti |
| 2026-01-15 | Deck | J. P. Morgan 2026 Healthcare Conference |
| 2026-01-12 | Press release | PDF Version |
| 2026-01-12 | Press release | Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference · 2025 |